6DXG

amidobenzimidazole (ABZI) STING agonists


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.91 Å
  • R-Value Free: 0.235 
  • R-Value Work: 0.193 
  • R-Value Observed: 0.195 

wwPDB Validation   3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Design of amidobenzimidazole STING receptor agonists with systemic activity.

Ramanjulu, J.M.Pesiridis, G.S.Yang, J.Concha, N.Singhaus, R.Zhang, S.Y.Tran, J.L.Moore, P.Lehmann, S.Eberl, H.C.Muelbaier, M.Schneck, J.L.Clemens, J.Adam, M.Mehlmann, J.Romano, J.Morales, A.Kang, J.Leister, L.Graybill, T.L.Charnley, A.K.Ye, G.Nevins, N.Behnia, K.Wolf, A.I.Kasparcova, V.Nurse, K.Wang, L.Li, Y.Klein, M.Hopson, C.B.Guss, J.Bantscheff, M.Bergamini, G.Reilly, M.A.Lian, Y.Duffy, K.J.Adams, J.Foley, K.P.Gough, P.J.Marquis, R.W.Smothers, J.Hoos, A.Bertin, J.

(2018) Nature 564: 439-443

  • DOI: 10.1038/s41586-018-0705-y
  • Primary Citation of Related Structures:  
    6DXG, 6DXL

  • PubMed Abstract: 
  • Stimulator of interferon genes (STING) is a receptor in the endoplasmic reticulum that propagates innate immune sensing of cytosolic pathogen-derived and self DNA 1 . The development of compounds that modulate STING has recently been the focus ...

    Stimulator of interferon genes (STING) is a receptor in the endoplasmic reticulum that propagates innate immune sensing of cytosolic pathogen-derived and self DNA 1 . The development of compounds that modulate STING has recently been the focus of intense research for the treatment of cancer and infectious diseases and as vaccine adjuvants 2 . To our knowledge, current efforts are focused on the development of modified cyclic dinucleotides that mimic the endogenous STING ligand cGAMP; these have progressed into clinical trials in patients with solid accessible tumours amenable to intratumoral delivery 3 . Here we report the discovery of a small molecule STING agonist that is not a cyclic dinucleotide and is systemically efficacious for treating tumours in mice. We developed a linking strategy to synergize the effect of two symmetry-related amidobenzimidazole (ABZI)-based compounds to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function. Intravenous administration of a diABZI STING agonist to immunocompetent mice with established syngeneic colon tumours elicited strong anti-tumour activity, with complete and lasting regression of tumours. Our findings represent a milestone in the rapidly growing field of immune-modifying cancer therapies.


    Organizational Affiliation

    Pattern Recognition Receptor DPU, GlaxoSmithKline, Collegeville, PA, USA.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Stimulator of interferon protein A191Homo sapiensMutation(s): 0 
Gene Names: STINGLOC340061hCG_1782396STING1ERISMITATMEM173
Find proteins for Q86WV6 (Homo sapiens)
Explore Q86WV6 
Go to UniProtKB:  Q86WV6
NIH Common Fund Data Resources
PHAROS:  Q86WV6
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
HGJ
Query on HGJ

Download Ideal Coordinates CCD File 
A
2-[(1-ethyl-3-methyl-1H-pyrazole-5-carbonyl)amino]-1-[(2R)-2-hydroxy-2-phenylethyl]-1H-benzimidazole-5-carboxamide
C23 H24 N6 O3
NMXJYHHOVIHSBO-FQEVSTJZSA-N
 Ligand Interaction
CA
Query on CA

Download Ideal Coordinates CCD File 
A
CALCIUM ION
Ca
BHPQYMZQTOCNFJ-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
HGJIC50:  14000   nM  Binding MOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.91 Å
  • R-Value Free: 0.235 
  • R-Value Work: 0.193 
  • R-Value Observed: 0.195 
  • Space Group: C 2 2 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 81.607α = 90
b = 92.221β = 90
c = 72.735γ = 90
Software Package:
Software NamePurpose
SCALEPACKdata scaling
PHENIXrefinement
PDB_EXTRACTdata extraction
HKL-2000data reduction
MOLREPphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2018-06-28 
  • Released Date: 2018-11-07 
  • Deposition Author(s): Concha, N.O.

Revision History 

  • Version 1.0: 2018-11-07
    Type: Initial release
  • Version 1.1: 2018-11-21
    Changes: Data collection, Database references
  • Version 1.2: 2019-01-02
    Changes: Data collection, Database references